Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc. is an American medical device company that designs, manufactures, and markets orthopedic reconstructive implants — hips and knees — along with a growing portfolio of sports medicine, extremities, trauma, craniomaxillofacial and thoracic products, and robotic surgical systems, generating $8.23 billion in revenue in fiscal 2025. Headquartered in Warsaw, Indiana, the company holds the number-one global position in hip and knee reconstruction and sells into more than 100 countries, competing principally against Stryker, Johnson & Johnson's DePuy Synthes, and Smith & Nephew.

This is a story about an incumbent franchise investing through a period of deliberate business-model change. Zimmer Biomet is midway through converting its U.S. sales force from a network of independent distributors to a fully dedicated, specialized employee channel — a multi-year undertaking that depresses near-term margins and has already cost it accounts in its most important product category. At the same time, it is integrating three acquisitions closed in 2025, rationalizing its knee implant portfolio around a single brand, and building toward the 2027 launch of an autonomous surgical robot that management believes can close the competitive gap with Stryker's Mako platform. The file turns on a single question: whether the company can execute this transformation without ceding so much ground in knees that the eventual payoff arrives to a smaller franchise.

The market is pricing the stock as though the answer is more likely "no" than "yes." At roughly $82 per share in June 2026, Zimmer Biomet trades at approximately 10 times the midpoint of 2026 adjusted EPS guidance and roughly 21 times trailing GAAP earnings — well below its historical median. The bull case is that the transformation works, margins recover, and the multiple re-rates toward the high teens, producing a substantially higher equity value. The bear case is that the company is fighting a two-front war — against Stryker's technological lead in robotics and against the internal disruption of its own commercial reorganization — and loses on both.